Pharmacogenetics of antidepressant response: A polygenic approach.

نویسندگان

  • Judit García-González
  • Katherine E Tansey
  • Joanna Hauser
  • Neven Henigsberg
  • Wolfgang Maier
  • Ole Mors
  • Anna Placentino
  • Marcella Rietschel
  • Daniel Souery
  • Tina Žagar
  • Piotr M Czerski
  • Borut Jerman
  • Henriette N Buttenschøn
  • Thomas G Schulze
  • Astrid Zobel
  • Anne Farmer
  • Katherine J Aitchison
  • Ian Craig
  • Peter McGuffin
  • Michel Giupponi
  • Nader Perroud
  • Guido Bondolfi
  • David Evans
  • Michael O'Donovan
  • Tim J Peters
  • Jens R Wendland
  • Glyn Lewis
  • Shitij Kapur
  • Roy Perlis
  • Volker Arolt
  • Katharina Domschke
  • Gerome Breen
  • Charles Curtis
  • Lee Sang-Hyuk
  • Carol Kan
  • Stephen Newhouse
  • Hamel Patel
  • Bernhard T Baune
  • Rudolf Uher
  • Cathryn M Lewis
  • Chiara Fabbri
چکیده

BACKGROUND Major depressive disorder (MDD) has a high personal and socio-economic burden and >60% of patients fail to achieve remission with the first antidepressant. The biological mechanisms behind antidepressant response are only partially known but genetic factors play a relevant role. A combined predictor across genetic variants may be useful to investigate this complex trait. METHODS Polygenic risk scores (PRS) were used to estimate multi-allelic contribution to: 1) antidepressant efficacy; 2) its overlap with MDD and schizophrenia. We constructed PRS and tested whether these predicted symptom improvement or remission from the GENDEP study (n=736) to the STAR*D study (n=1409) and vice-versa, including the whole sample or only patients treated with escitalopram or citalopram. Using summary statistics from Psychiatric Genomics Consortium for MDD and schizophrenia, we tested whether PRS from these disorders predicted symptom improvement in GENDEP, STAR*D, and five further studies (n=3756). RESULTS No significant prediction of antidepressant efficacy was obtained from PRS in GENDEP/STAR*D but this analysis might have been underpowered. There was no evidence of overlap in the genetics of antidepressant response with either MDD or schizophrenia, either in individual studies or a meta-analysis. Stratifying by antidepressant did not alter the results. DISCUSSION We identified no significant predictive effect using PRS between pharmacogenetic studies. The genetic liability to MDD or schizophrenia did not predict response to antidepressants, suggesting differences between the genetic component of depression and treatment response. Larger or more homogeneous studies will be necessary to obtain a polygenic predictor of antidepressant response.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Pharmacogenetics of Antidepressants, A Review of Significant Genetic Variants in Different Populations

Major depressive disorder is a highly prevalent disease that is challenging to treat, often requiring medication and dose adjustments. Genetic factors play an important role in psychotropic medication responses. However, the translation of pharmacogenetics findings to clinical recommendations with regards to antidepressant responses is still in its early stages. We reviewed recent primary resea...

متن کامل

Pharmacogenetics of Antidepressant Drugs: An Update

Pharmacological treatment of depressive disorders is characterized by poor predictability of individual response. In recent years, the increasing evidence has demonstrated that genetic factors play a critical role in determining the differences in treatment outcome to antidepressant drugs. A number of pharmacogenetic studies on antidepressant drugs has been conducted, and genetic variations at ...

متن کامل

I-33: Pharmacogenetics of Reproductive Medicine

Adverse drug reactions (ADRs) are a major problem in drug therapy and drug development. Inter-individual genetic differences can have significant roles in determining an individual’s susceptibility to ADRs. The rapid development of techniques in the area of genome analysis has put the scientific community in a power position and facilitated identification of new pharmacogenomic biomarkers that ...

متن کامل

I-24: Individualized Controlled Ovarian Stimulation (iCOS)

Background: With the recent development of recombinant gonadotropins (FSH and LH), it has become possible to further adjust the stimulation protocol according to the expected needs of the patient. In this respect, the possible beneficial role of exogenous LH activity supplementation for stimulated ART cycles has received increasing attention. According to the two-cell, two- gonadotropin theory,...

متن کامل

Aberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapy.

We investigated the accumulation of aberrant CYP2D6 genotypes and predicted metabolizer phenotypes (ultrarapid metabolizer, intermediate metabolizer and poor metabolizer) potentially affecting the antidepressant treatment response in depressive patients indicated for electroconvulsive therapy (ECT) compared with patients with a single episode of depression. Seventy-six Dutch White patients with...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Progress in neuro-psychopharmacology & biological psychiatry

دوره 75  شماره 

صفحات  -

تاریخ انتشار 2017